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ABSTRACT 
The thesis is about the cost utility analysis (CUA) of the treatment of HIV/AIDS in Ghana. 
One hundred and six participants took part in the study. Participants of this study were People 
Living with HIV/AIDS. These are clients in two different clinics in Ghana-the Fevers’ Unit of 
the Korle Bu Teaching Hospital and the Health for All Herbal Clinic. Two treatment 
strategies were considered. The treatment strategy at Fevers’ Unit is the ARV drugs, while the 
treatment strategy at the Health for All Herbal Clinic is the herbal treatment, DnT Veramin 
1&2. Questionnaires were administered to the participants to elicit information about their 
demographic characteristics, their annual cost of HIV/AIDS treatment and their effect 
measures. The effect measures are QALY taken from EQ5D5. These outcome measures were 
calculated from the societal perspective and the individual payer perspective. The incremental 
cost effectiveness ratio (ICER) was calculated. Results show that ARV treatment is cost 
effective. From the societal perspective, The ICER is GHC3,493 per QALY when the 
productivity cost is included and GHC3,193 per QALY (when productivity cost is excluded). 
From the individual health care payer perspective, the ICER is GHC860 per QALY when 
productivity cost is included and GHC560 per QALY when productivity cost is excluded. The 
willingness to pay (WTP) is set at the GDP per capita of Ghana, which is GHC5,022. When 
the computed ICERs are compared with the per capita GDP of GHC5,022 per QALY, the 
ICER values are less.  This shows that the ARV treatment is cost effective, and policy makers 
and all stakeholders should (all things being equal) implement programmes to scale up ARV 
treatment for PLWHAs. 
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CHAPTER 1: INTRODUCTION 
1.1 Background  
Ghana’s Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome 
(HIV/AIDS) epidemic status has been categorised as ‘‘generalised.’’ This means that the 
country has not been hard hit by the HIV/AIDS epidemic like other countries in sub-Saharan 
Africa (Rosen and Asante, 2010).  The estimate of (median) prevalence for HIV/AIDS in 
Ghana was about 2 per cent of the population. However there are variations between urban 
areas and rural areas. The urban areas have the higher prevalence rate, with Agormanya 
recording prevalence of 7.8 per cent (Rosen and Asante, 2010).  
The HIV/AIDS epidemic has been a source of great drain to the economy.  Much resource is 
committed to financing many diverse aspects of the sickness.  For instance in 2007 alone, an 
amount of USD52,445,091 was allocated for HIV/AIDS related programmes. About 42 per 
cent of this money was committed to HIV/AIDS treatment and care (Asante and Fenny, 
2008). 
The introduction of antiretroviral (ARV) therapy was a great watershed in the history of 
HIV/AIDS. This has had a great improvement on the health of people living with HIV/AIDS 
(PLWHA), enabling them to live longer (Doran, 1997). According to the joint United AIDS 
document, there is an increase in access of ARV to PLWHAs in sub-Saharan Africa, resulting 
in some level of decline in HIV/AIDS related morbidity and mortality. There has also been 
significant increase in access to ARV for pregnant women resulting in reduction in mother to 
child transmission (MCT). For instance, in 2009, 37 per cent of PLHWA had access to ARV 
in sub - Saharan Africa. Also, about 54 per cent of pregnant women received treatment to 
prevent MCT.  There was 20 per cent decrease in HIV/AIDS related deaths in the region, and 
a significant decrease in HIV/AIDS among children (UNAIDS, 2010). However, there are 
still problems with access. A cursory look at the statistics above showed that, since total 
coverage of ARV treatment was estimated to be 37 per cent, then about 63 per cent of the 
total population of PLHWAs do not have access to ART. There is therefore a need to scale up 
efforts to increase the access to treatment. There is also the need to undertake thorough 
studies, to establish whether the ARV treatment and scaling-up the treatment programmes 
2 
 
will significantly reduce, if not totally eliminate the HIV/AIDS epidemic in sub-Saharan 
Africa. 
Since the emergence of the HIV/AIDS, there have been efforts from various stakeholders to 
explore ways of finding local (traditional) medicine for the treatment of the disease. There has 
been evidence that people living with HIV/AIDS use traditional medicine (Babb, et al, 2004). 
In an effort to manage the disease in South Africa, some people living with HIV/AIDS use 
hypoxis and sutherlandia (Mills, Cooper, Dugald and Kanfer, 2005), although the 
effectiveness of these treatment options have not been established. 
The World Health Organisation (WHO) defines traditional medicine as: 
‘‘ health practices, approaches, knowledge and beliefs incorporating plant, animal and mineral 
based medicines, spiritual therapies, manual techniques and exercises, applied singularly or in 
combination to treat, diagnose and prevent illnesses or maintain well-being.’’ (WHO,  2003). 
From the above definition, it could be deduced that traditional medicine is based on both spirit 
and the material. The material part of healing enables the traditional medical practitioners to 
use herbs which include plants to prevent or cure diseases. 
The traditional medical practitioners seem to be the first point of call, especially in Africa 
where they are used for treatment for ailments including HIV/AIDS. This is because they are 
readily available and their cost of treatment is affordable (Langlois-Klassen, Kipp, Jhangri, 
Rubaale, 2007). A common knowledge about some shortcomings of the traditional medical 
practice especially in Afrcia is that the traditional medical practitioners do not have any 
effective ways of diagnosing HIV/AIDS. They also do not observe basic hygienic practices 
thus exposing their clients to other infections. Finally, there has not been any systematically 
conducted study to establish the effectiveness of any of the traditional medical preparations. 
In Ghana, a herbal practitioner, called Dr. Normeshie, owner of Health for All Herbal Clinic 
has developed the DNT veramin 1 and 2, which seem to have anti-retroviral agents. Some 
people living with HIV/AIDS have been using this therapy and seem to be doing well.  Plans 
to conduct scientifically proven clinical efficacy of the treatment is underway, however, Dr 
Normeshie has organised some of the HIV/AIDS clients in his clinic into providence groups, 
who meet periodically for seminars on how to combat the challenges of living with 
HIV/AIDS (ankwa-roots.org). A word of caution here is that though DNT Veramin 1&2 
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herbal treatment appears to improve the quality of life of the people using it, no empirical 
study has been done to establish its efficacy or effectiveness. It has been established that ARV 
treatment is cost effective. No direct evidence show cost effectiveness of herbal drugs in 
treating HIV/AIDS. Evidence shows that the mere fact that PLWHA receive care from others 
improves their health (Gatsi, 2008).  Due to the fact that herbal treatment may increase 
QALYs and is much cheaper than ARV, one cannot rule out totally herbal drugs being cost 
effective. This may influence the health gains from the clients receiving DNT veramin 1 and 2 
treatment. This study therefore uses the veramin 1 and 2 treatment as control, rather than 
effective treatment.  
1.2 Rationale of the study 
The search for a cure for HIV/AIDS has for some time now eluded the research community.  
HIV/AIDS is not affecting only the health of the people. It affects the economic activities of 
the people, as victims who are sick may not be able to engage in productive activities. They 
may not be able to earn decent incomes. Their loss of income may not affect them alone, but 
also their dependants. Anti-retroviral therapy has been seen as the stop gap solution for 
HIV/AIDS treatment as it helps increase the life span of the PLWHAs and also helps them to 
take part in productive economic life. As discussed above, the challenge of using anti-
retroviral therapy in HIV/AIDS in many sub-Saharan Africa countries is the cost. Many 
people cannot afford the treatment and thus making coverage as low as just above 30 per cent. 
Some traditional herbal practitioners have developed herbal treatment options for treating the 
disease. However, the efficacy of such traditional treatment alternatives has not been 
adequately proven. ARV treatment is thus the only viable option. There is therefore the need 
to find affordable ways of treating people living with HIV/AIDS. Treatment cost is not the 
only challenge for people living with HIV/AIDS, other costs included transportation and time 
among others. 
The discussion above throws a challenge for the research community, and therefore this study 
intends to: 
1. compare the costs and effects of the scientifically proven Antiretroviral drugs to the DNT 
veramin 1&2 in the treatment of HIV/AIDS . 
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2. calculate the Incremental cost effectiveness analysis (ICER) for the alternative 
programmes. 
This study is conducted as a trial base study. The study also covered only a year. This is 
consistent with a trial based study done by Torrance, Raynauld, Walker et al. (2002), where 
they compared two treatment strategies for osteoarthritis. Since this study is also trial based, 
and covers only one year, modeling will not be done for the cost utility analysis. 
1.3 The research areas 
The two research areas, the Fevers’ Unit of the Korle Bu Teaching Hospital and the Health 
for All Herbal Clinic are described below. 
1.3.1 Fevers’ Unit of Korle Bu Teaching Hospital  
The Fevers’ Unit at Korle Bu Teaching Hospital handles treatment for HIV/AIDS related 
conditions. The unit has been operational since 2003. Some physicians and other support staff 
render services for the HIV/AIDS clients. Services carried out include voluntary counseling 
and testing (VCT) whereby clients are screened for HIV/AIDS infection, administration of 
ARV treatment, prevention of mother to child transmission (PMTCT) and other related 
services. The various assessments show that the minimum of five Ghana Cedi (GHC5.00 ) 
payment for ARV drugs is affordable for some fractions of patients visiting the unit, even 
though some could still not afford it (uneca.org). 
1.3.2 Health for All Herbal Clinic  
The Health for All Herbal Clinic started work in 1984, in Owuram a village located along the 
Asamankese – Suhum road. This herbal centre provides treatment for many ailments using 
herbal medicine. The clinic also serves as research centre for herbal medical research. The 
Health for All Herbal Clinic has in co-operation with the Ananse Village Programme started a 
providence group for clients of the clinic who report to have HIV/AIDS related ailments. 
Apart from giving herbal treatment for the clients in the clinic, the clients are also given 
couselling services. The herbal centre has teamed up with a non-Governmental organisation 
(NGO) to provide some small credit to boost the economic activities of members of the group 
(http://www.ananseghana.org/healthforall). The DNT veramin 1 and 2 is supposed to be given 
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to the clients free but practically some small amount of money is taken from clients and some 
extra herbal drugs are also supplied for which they pay for. It is clear that the treatment is not 
wholly free. The services of the Health for All Herbal clinic is patronised largely by people in 
its catchment areas. The HIV/AIDS services are relevant alternatives to people who could not 
afford the cost of ARV drugs and transport costs to Accra and other places where HIV/AIDS 
services provided by public sector health care facilities are located. Proximity is an important 
factor in healthcare assessment therefore location of this clinic is relevant in this study. 
1.3.3 Geographical Location of the Research Areas 
The geographical locations of the research areas are presented in figure 1 below. The map 
shows the research sites. 
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Figure 1: The map showing an Africa map with Ghana and the research locations within Ghana. 
Footnote: the maps were taken from google.com/maps. I organized them myself. 
 
 
 
 
The research area of the ARV intervention, the Fevers’ unit is located in the Accra 
metropolis, Ghana’s Capital. The Accra area has a very diverse status as people from all over 
the country and beyond live in the metropolis. The city population is estimated to be about 
two million people. It is estimated that migration contributes to the population increase.   
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There are the very wealthy people living in upscale communities and the very poor people as 
well. The city has major health care facilities including the Korle Bu Teaching Hospital which 
houses the Fevers’ Unit (www.ama.ghanadistricts.gov.gh/) 
The research area for the herbal intervention, Health for All Herbal Clinic is located at 
Owuram village in the West Akim Municipality in the Eastern Region of Ghana. The Village 
is located about 13 kilometers from Asamankese, the municipal capital. The West Akim 
Municipality covers an area of about 1 018 square kilometers.  Asamankese, the municipal 
capital is about 75 kilometers from Accra. The Municipal Assembly is bounded in the North 
by the Kwaebibrem District, the Birim South Municipal assembly to the West. The Agona,  
Awutu and Ga East Municipal to the South, and Suhum-Kraboa-Coalter and the Akwapim 
South Municipal Assemblies in the East. 
The main economic activities  that form basis for household income in the area are crop 
agriculture, business/ trading, family workers’ salaries, manufacturing, food processing and 
remittances. Agriculture forms 40 per cent of the income of the people in the area. The 
incidence of poverty is quite high in the area.  The landscape of West Akim Municipality is 
very rich and support both cash crop and food crop cultivation. There are also deposits of 
minerals like gold and diamond in commercial quantity in the Municipality. The population of 
the municipality is estimated at about 166 000.  
 The health infrastructure in the municipality includes one municipal hospital, three clinics 
and six health posts. The Health for All Herbal Clinic also provides significant health services 
to the people. There are only two medical doctors in the municipality with the nurse to patient 
ratio at one nurse to about 3000 patients 
Malaria and infectious diseases are among the most common causes of consultations in the 
health centers and remain the most common causes of death in the area. 
The VCT service in the municipality has not been encouraging. It must be noted however 
that, people who patronise health care facilities come from different places, and thus there are 
people resident outside the municipality who assess health care in the health centers located in 
the municipality. HIV/AIDS has been identified as a major concern in the health system in the 
Municipality (http://westakim.ghanadistricts.gov.gh/). 
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From the above it is very clear that there are still serious challenges in the health delivery 
system in the two research sites and the Ghana as a whole. It is also very prudent that the 
scarce resources for the interventions are evaluated to ensure that they are being put into 
judicious use. Finally an evaluation also ensures that decision makers are guided by empirical 
evidence in their quest to implement their policies.  
The two research areas are very diverse. The Fevers’ Unit is urbanized whiles the Health for 
All Herbal Clinic is located in the rural area. This disparity plays much role in access and 
delivery of health care. Major health care programmes and facilities are in the urban areas. 
There are also higher economic activities in the urban area resulting in higher income and 
higher socioeconomic status in the urban areas. The effects outplay in access to HIV/AIDS 
treatment and care cannot be overemphasized. 
1.4 Economic evaluation of health care programmes 
The major issue in Economics is the scarcity of resources. This entails that individuals and 
society give up some resources in order to get some other (Folland, Goodman and Stano, 
2010). According to Drummond et al. (2005), when we say economic evaluation, we are 
talking about the cost and consequences of a programme that allow us to make a decision on 
how scarce economic resources are to be used. To undertake an economic evaluation, the 
various cost elements of the activities being conducted must be identified, measured, valued, 
and compared with the effect of each of the activities or programmes. These enable choices to 
be made for the best alternative programme. There are various types of economic evaluation. 
These include cost effectiveness analysis (CEA), cost utility analysis (CUA), and cost benefit 
analysis (CBA). The three techniques are similar in the identification and valuation of costs. 
The only differences are how the effects are measured in the various techniques. Due to 
scarcity of resources, conducting economic evaluation helps determine efficient allocation of 
health care resources. Further it ensures that the various interventions are compared to 
determine which ensures better health, and also helps decision makers, operating within a 
given budget, choose between alternative programmes (Gold et al 1996). 
1.4.1 Cost effectiveness analysis 
Cost-effectiveness analysis (CEA) is the type of economic evaluation in which the various 
cost elements of the programme are related to a single common effect, and this effect may 
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differ in magnitude between the alternative programmes. The cost effectiveness analysis can 
only be conducted on programmes that have a common effect, which are stated in natural 
units (Drummond et al, 2005). In CEA the estimate is comparing a nonmonetary objective, 
for example lives saved. In CEA the net or incremental cost of an intervention is estimated. 
The estimate involves the cost of the health outcomes of the programme. The main objective 
of conducting a CEA is to compare the relative value of different interventions in creating 
better health, longer life or both.  
1.4.2 Cost Utility Analysis 
According to Drummond et al (2005), in cost utility analysis (CUA), the measure under 
consideration is the Quality Adjusted Life Years (QALY) or some variants health outcome 
derived by the society or individuals. Utility of various health outcomes differ from one 
individual to the other and from society to society. This must be taken into consideration to 
determine the economic evaluation of a programme. The CUA is thus a variation of cost 
effectiveness analysis where the measures of benefits reflect the individuals’ or society’s 
preferences over the health effects of alternative programmes.  An advantage of using utility 
analysis is that the health related quality of life adjustment to treatment outcome and generic 
comparisons of the outcomes can be simultaneously calculated for the given costs and 
outcomes of different programmes under consideration. The main generic outcomes include 
quality adjusted life years (QALY), healthy years equivalent (HYE), and Disability Adjusted 
Life Years (DALY). 
The CUA results are usually presented as incremental cost per healthy year gained or cost per 
quality adjusted life year gained for undertaking one programme rather than another 
programme. 
1.4.3 Cost benefit analysis 
The third form of economic evaluation worth discussing is the cost benefit analysis (CBA). 
The cost benefit thus combines both the cost and consequences of alternatives under 
consideration in monetary terms. The CBA requires that we place monetary values on 
improvements in life and well-being from a project. The results of CBA are presented as ratio 
of cost to benefit. In CBA, when the monetary benefits of a project exceed the costs, then the 
project is worth undertaking (Drummond et al, 2005). However, since it is difficult to value 
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the benefits of health gains to society in monetary terms, CBA is not much used in health 
economics.  
1.4.4 Cost Minimization Analysis 
Sometimes, economic evaluations are referred to as Cost Minimisation Analysis (CMA). Cost 
minimisation analysis describes a situation where the effects of the treatment options being 
considered are broadly equivalent. The cost of the treatment options determines which of 
them to choose (Drummond et al, 2005 
According to Drummond et al (2005), the methods of economic evaluation identified above 
have similarities and differences. They may have similar cost elements. However, they differ 
at the effects side. For instance measures of effect in CEA are single, programme specific and 
unvalued. However, effect measures in CUA may be single or multiple. They are not 
programme specific but generic. They are also preference based. The CUA also have broad 
applicability. It is therefore more useful by decision-makers than CEA. It is also more useful 
than CBA because of the difficulty in placing monetary value on health outcomes, which the 
later measures.  
It must be noted that classifying study types or techniques are just a way of identifying that 
completed studies have different analytic characteristics. It does not prescribe a particular 
study because in the beginning of every study, it is difficult to identify a study type in 
advance, as data may not be available. Also different approaches could be combined to 
conduct an analysis, since each could explore various dimensions of the study. The objective 
of the study spelt out by the decision-maker drives the choice of the form of study.  However, 
Gold et al, (1996), stated that the three various techniques (especially CEA and CUA) are not 
very different and can be used interchangeably. My study uses CUA. Also, expected quality 
of life is an important aspect of herbal treatment from the herbal clinic, and this can be 
assessed using CUA. In standard economics, we usually read utilities as ordinal, but in health 
economic evaluations the preferences are cardinal therefore calibrating them as utilities is 
ideal. 
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1.4.5 Measure of Health-Related Quality of Life (HRQoL) 
There are various gains in health measures associated with programmes during economic 
evaluations. Some of these are explained below. 
In most health care programmes, one significant economic benefit of an intervention is the 
improvement in quality of life (Drummond et al, 2005). The Health-Related Quality of Life 
(HRQoL) is the effect of a disease on the way a person enjoys life, which includes the way 
illness affects a person’s ability to live free of pain, to work productively, and to interact with 
other people. The HRQoL score thus translates a perception of quality into a number 
(Muening, 2002).  
There are various tools, developed to measure Health Related Quality of Life (HRQoL). 
These include Life Years gained (LY), Disability Adjusted Life Year (DALY) and Quality 
Adjusted Life Years (QALY), among others.  
The Disability Adjusted Life Years (DALY) was used in the World Health Report in 1993 
conducted by the World Bank.  DALY is a measure of disease burden.  It measures the 
number of years lost to a disability, illness, or death. The DALY assigns disease weights to 
health outcomes, where the value 0 equals full health and 1 equals death. DALYs may also be 
adjusted for age and sex. 
Some criticisms have been leveled against the DALY.  This measure is biased towards the 
poor and the elderly in society. In order to use DALYs, one needs to discount for age and sex, 
however, it has been argued that these two variables are not the only sources of disparities 
among populations. Socioeconomic factors are also a source of disparities and thus DALYs  
discriminate against people from low socio-economic backgrounds (Robberstad , 2005).  
DALY is not used in this study because an analysis using DALYs would have a bias against 
relatively poor and elderly people compared to relatively rich and middle age people in the 
study in Ghana. 
Drummond et al (2005) explained that when using the Quality Adjusted Life Years (QALYs), 
premature death and morbidity are combined, while weights are assigned to health states. The 
QALY attempts to estimate the number of years that could be added by an intervention. Each 
year lived is given a value. The value 0 is equal to death, while the value, 1 equals perfect 
health. The QALY of an individual is a product of the health related quality of life of the 
12 
 
health state and the duration of the health state. This study uses QALYs because unlike 
DALYs, results of QALYs are not biased against people of lower socioeconomic status. 
The weight values of QALY are determined by the methods listed below: 
Standard Gamble: This is a preference based measurement based on von Neuman 
Morgenstern utility theory. A core issue of measurement using the standard gamble is the 
preferences between two prospects. For the first prospect, you live with your current chronic 
disease while for prospect 2 you either die immediately or you regain full health.The patient is 
given given a choice of a treatment that has two options, either the patient is restored to 
perfect health and lives for some additional years or the patient dies immediately. 
Alternatively, the patient remains with the chronic state for life. The options are varied until 
the patient becomes indifferent to the two prospects. Standard gambles can be obtained from 
patients by face to face interviews, paper based approaches, group interviews among others.  
Time Trade Off: Here the respondents are asked to make a choice between staying in an ill 
health conditions for a period of time and undergoing a medical intervention that has a 
potential of restoring them to perfect health but with a shorter life. The individual is to decide 
what length of time he or she is to live in full health which would make him indifferent 
between that and the current. In effect, the individual is answering the question ‘‘how much 
time are you willing to forgo in order to live the rest of your life in full health?’’ 
Visual Analogue Scale: Respondents are asked to rate their state of ill health condition on 
scale from 0 to 100. The score of zero represents death, while 100 represents perfect health 
Apart from the above methods, EuroQol Group has developed a questionnaire based measure 
called EQ5D5. The EQ5D5 has two parts of measurement. The first part is a descriptive 
system which categorizes health states according to the following dimensions: mobility, self-
care, usual activities (e.g. work, study, homework or leisure activities), pain/discomfort and 
anxiety/depression.  However, each dimension has 5 levels: no problems, slight problems, 
moderate problems, severe problems, and extreme problems. The interviewee ticks the level 
that corresponds to the dimension of his or her health. The part two of the questionnaire 
includes an EQ Visual Analogue Scale, which is a 20 cm vertical visual analogue scale with 
endpoints labeled as ‘‘the best health you can imagine’’ at the upper end point and ‘‘the worst 
health you can imagine’’. The scale is calibrated from 0 to 100.  There is a box below the 
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VAS scale. The respondents are instructed to mark an X on the scale to indicate their health 
on the day of filling the questionnaire. The score marked on the VAS scale is then recorded 
on the box below the VAS scale (EuroQol Group, 2011). 
The health dimension scores from the health state scores computed to develop the QALY. 
This study will use the EQ5D5L to collect the QALY data. Through periodic researches and 
reviews using different population groups and cultures, the EQ5D5 scale has been adapted 
and various scores computed for different cultures. In sub-Saharan Africa, the questionnaire 
has been adapted for use in South Africa, based on the UK value sets. The EQ5D5 value sets 
are developed into QALYs.The QALY scores have also been adapted for Zimbabwe. This 
study will use the conversion scale for Zimbabwe to measure the QALY measures for the 
participants (EuroQol, 2011). Zimbabwe is in Sub-Saharan Africa, and shares some 
development trends with Ghana. This country thus serves as an ideal proximate measure of 
the QALYs for Ghanaian participants in this study. 
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CHAPTER 2: THEORETICAL FRAMEWORK AND 
LITERATURE REVIEW 
2.1 Theories and Perspectives  
This chapter deals with the relevant theories and perspectives upon which this study rests. The 
theories and perspectives are relevant to throw more light on the research topic and findings. 
These include von Neumann- Morgenstern utility theory, welfarist theory, societal perspective  
and individual patient perspective. In conducting economic evaluation of various health care 
programmes, it is expedient to identify the various cost elements that the programme entails 
and also the consequences. The perspective taken determines which cost to include and which 
to exclude. 
2.1.1 Expected Utility theory 
The expected utility theory which is also called the Neumann-Morgenstern utility theory,  is a 
theory developed to describe how rational individuals ought to make decisions in terms of 
uncertainties. According to this theory, alternative actions have possible outcomes. Each 
outcome has set of corresponding probabilities. The preferences of these outcomes are given 
quantitative values, which have cardinal or ordinal characteristics. (von Neumann and 
Morgenstern, 1944). In health, the outcomes are seen as cardinal. The utilities of each 
outcome are multiplied with its probability. The products are summed for each outcome and 
to determine the expected utility (Drummond et al, 2005). 
2.1.2 The Welfarist Perspective 
 The welfarist perspective considers the value the individuals place on outcomes, because they 
assumed the individuals to be the best judges of their welfare. The welfarist thus determines 
the amount the individual is willing to pay for the programme, in evaluating the cost-
effectiveness of the programme (Drummond et al, 2005). Garber, Weinstein, Torrence (1996) 
explained that overall welfare of society is derived from the individual perferences. According 
to the welfarist perspective, the utility of individuals depends on their consumption, and this 
utility and preferences function follow certain conditions of rationality and logical 
consistency. Also, they posit that aggregation of individual preferences makes up welfare of 
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society. This means that in designing programmes, decision makers need to among other 
things consider how the combination of resources affects the welfare of the society.  
2.1.3 Societal perspective 
According to Muenning (2002)  a study is said to be conducted from a perspective when a 
group or organisation’s need influences the costs and outcomes that are selected into the cost 
utility analysis. The societal perspective involves taking into consideration all costs relevant 
to the analysis into the study. A nice way to standardize cost effectiveness analysis is to 
require that all cost-effectiveness analysis assume the same perspective. The reference case 
scenario of the Panel on cost effectiveness in Health and Medicine requires that the societal 
perspective be adopted (Gold, et al, 1996). Also, according to Hunink, Glasziou et al (2001), a 
prime benefit of CEA (in this case CUA) is to allow decision makers to compare and make 
choices among programmes, therefore it is imperative that there be a bank of comparable 
CEA. Societal perspective ensures this comparison. This study will also assume the societal 
perspective. 
It is very important to calculate the cost and effects of an intervention relative to other 
interventions.  In cost effectiveness analysis the cost of an intervention, the quality of life and 
the number of years of life gained are combined into a ratio called the cost effectiveness ratio. 
The formulae for calculating the cost effectiveness ratio is presented below: 
                                 
                                                        
                                
     (1) 
 The cost – effectiveness ratio shows how much an intervention costs relative to the number 
of QALYs gained in the cohort. A disadvantage of the cost effectiveness ratio however, is that 
it does not provide information on how the intervention compares to other strategies for 
treating the disease under consideration. 
When a study intends to do comparison between interventions the appropriate formula to use 
is the incremental cost – effectiveness ratio.  
In an incremental cost effectiveness ratio, two or more active options for interventions and 
their effects are compared. The incremental cost effectiveness ratio (ICER) is thus the added 
cost per unit of added benefit of an option, relative to the next less expensive choice (Hunink, 
2001).  
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The formula according to Muening, (2002) is given below  
                         ICER= 
                                                         
                                               
    (2) 
In my study where the interventions included ARV treatment and the DNT Veramin 1 & 2 
herbal treatment, the ICER will be given as: 
                                      
                            
   (3) 
 
The measure of a cost is the value forgone when resources are used for one purpose rather 
than the next best alternative. According to Drummond et al (2005), the cost of a programme 
is made up by the resources consumed by the programme. To determine the cost of the 
programme, quantities of the programme are calculated and then multiplied by the appropriate 
prices. The resources consumed in the health care programme may include costs in the health 
sector, and societal costs incurred by patient or family and then productivity losses.  
Health care sector costs may arise from items such as drugs, lab tests, physician visits etc. 
Health care costs may also include follow up visits. Resources from other sectors may include 
voluntary work. The resource use by patient and family may include cost of travelling to the 
hospital, and various out of pocket payments for the medicines.  
According to Drummond et al, (2005) an important decision in cost effectiveness study is to 
determine which costs to be considered in a specific study. The types of costs involve in a 
study is influenced by some factors explained below: 
1. The view point of the analysis: the view point of a study determines the type of costs to be 
included in the study. This is because an item which may be a cost at one point of view may 
not be a cost at another point of view. For instance when a patient spent extra money on a 
special diet recommended by the physician, as part of his treatment, it may be a cost from the 
patient’s perspective and the societal perspective, but that may not be a cost from the insurer’s 
perspective. Also, even though transfer payments, like worker compensation payments are 
cost to the paying agencies, gain to the worker, they are neither gain nor cost to society. 
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2. Scope of comparison: costs that are common in studies with scope narrowed down to 
programmes immediately under study can be eliminated. This could reduce the work load 
involved in the studies, without affecting the choice between the programmes under study. 
However, if a broader comparison and other alternatives will be included at a later time, then 
all the other costs should be included in the analysis. 
3. Ranges of cost: an economic analysis may turn out only to confirm results that will be 
obtained by considering a narrower range of costs. In this case, these costs can be eliminated 
without influencing the choice of programme. Eliminating such costs can simplify the 
analysis. In this case reasons for excluding such costs should be stated. 
4. Order of magnitude: the order of magnitude of the costs should also be considered. Cost 
effectiveness analysis requires a great deal of resources, therefore costs that are so 
infinitesimal and thus could not affect the outcome in any meaningful way could be 
eliminated. Reasons for eliminating such costs, for instance based on empirical studies can be 
given as basis to eliminate such cost items.  
A very important aspect of analysis after identifying costs is assigning values and measuring 
each individual cost item. This means that costing involves measuring quantities of resource 
use and assigning unit cost (i.e. price). Measuring quantity of resource use can be done in 
different ways. It can be collected on case report form when economic analysis is done 
alongside clinical trial. Some resource quantity data can be collected by review of patient 
charts or hospital records, or by asking patients. In theory, resource cost is its opportunity 
cost. However, in practice (health care) resources are valued at their market price. Sometimes 
the market price may differ from the actual price of resource consumed. For instance when 
the health care resource is subsidized in a specific hospital, the price will be different from the 
market price. This transfer cost representing the difference is not the major factor directing 
this study. There are uncertainties whether the opportunity costs represent the market price in 
this situation. However, since most of the cost items are paid out of pocket from the patients, 
we based it on opportunity costs as these represent values that may have alternative use. 
Values of non-market items: when people are sick, they spend their own time seeking health 
care. Also family and friends also give their time to support the recovery process of the 
patient. These are non-market resources and needed to be given a price tag for good 
evaluation. These times are sometimes evaluated using market wage rate. However some 
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studies exclude volunteer hours from friends and family. But in using societal perspective, 
patients’ time spent on accessing health care form a core part of resource cost.  
Adjustment of market prices: mostly, due to the imperfection of the health care market, the 
market prices differ greatly from opportunity cost. Hospital charges by hospitals operating as 
a monopoly may not reflect the market price of the health care charges. There may be the 
need to adjust for some of these charges in order to reflect the market price. However some 
studies use health care cost unadjusted. Health care cost may be adjusted if there is a clear and 
objective way of making the adjustment. They may also be adjusted if leaving them 
unadjusted could result in serious biases in the study outcome. 
Unrelated health care costs: there are health care costs that may be due to a certain health 
care intervention. For instance, children kept alive after a vaccination programme against 
whooping cough and measles will grow old. They may be sick of something else and still 
enjoy health care. The question arises whether the health care costs unrelated to the main 
intervention should be included in the analysis. Some pundits argue that health care costs in 
later years results from keeping the individual alive. This point of view agrees with the view 
that health care costs in later years should be included in the analysis. Others see this as unfair 
to assign other unrelated health care costs to a previous intervention. A suggestion to guide in 
making a stand in this debate is to determine whether there are enough data and also the 
extent to which a relationship could be established between the health care intervention under 
evaluation and the additional care of added years 
Capital outlay and overhead costs: health care programmes or interventions are not delivered 
in a vacuum. Structures are involved in implementing the programmes. For instance 
HIV/AIDS treatment programmes that we are working on are done in a hospital setting. Some 
of these structures include buildings, equipment, fixtures and fittings among others. These are 
examples of fixed assets. A characteristic of fixed assets is that they are used for many 
different programmes or interventions. Also, their uses extend into the future and do not end 
even after a single intervention, but are used over time. Finally a huge amount of money is 
invested in providing these assets. The cost involved in providing for these are called capital 
costs, since they include the injection of major capital. In economic evaluation, the 
depreciation of the capital cost can be calculated and used in the study. Also, they annuitize 
the initial capital over the useful life of the asset. An illustration where all costs are expressed 
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on annual basis by obtaining an equivalent annual cost could be important to explain the 
capital cost. The formulae from Drummond et al (2005) is expressed below 
  
 
     
 
 
      
   
 
      
  
Where K= capital, n period, r interest 
The E, which is the annuity factor is always taken from a table provided. 
Let us say that a hospital  have an investment of GHC 60 000 on a CT scan machine that is 
assumed to last for ten years and where 1/5 of the services it provides goes to your 
programme. Assuming an interest rate e.g. 3,5%, the equivalent annual cost (E) can be 
calculated using the formulae 
E = K/A 
A=annuity factor and is calculated by the formulae 
Annuity factor  
         
 
 
 What you get is A=0,291081/0,035=8,316605. E = K/8,316605=7214,482.  
Of this 1/5 goes to your project, i.e. 1442,89 each year. 
Apart from capital costs, other resources serve different programmes and departments. For 
instance in a hospital, radiography department and hostel also use same lighting, heating 
among others. Also laboratory equipment can be used for various tests. Light, computers, and 
other equipment in the lab can be used for different departments like HIV/AIDS, maternity 
and gynecology. These are known as overhead costs. Since these costs are shared by different 
departments, assigning the whole cost to one programme will inappropriately inflate the cost 
of the programme. The overhead cost per programme is computed based on method called 
allocation basis. By this some methods are used to apportion overhead costs to programmes or 
interventions that incurred them. The overheard costs can be allocated using direct allocation, 
where the overhead cost of a programme is allocated directly to the programme using 
allocation bases.  For instance, let us assume a hospital has HIV/AIDS treatment programme 
that runs ten hours per month.  Another programme also runs for fifty hours. The total lighting 
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cost of GHC 6000 will be (10 x 6000)/60 to the HIV/AIDS department. Other issues to 
consider are whether future costs should be considered and the rate of discounting these future 
costs. 
Other concerns on costing include adjusting for differential timing of costs. Individuals turn to 
have preference for benefit earlier than later, and to incur cost later than earlier. Also the 
value for cost items today may be higher than in the future. These should be taken into 
consideration in calculation cost of treatment or interventions. 
 Rosen and Asante (2010) used the systems approach which ensures that all inputs involved in 
an HIV/AIDS treatment are accounted for.  They identified the major type of costs for 
HIV/AIDS treatment in Ghana as costs for labour, capital, supplies. They itemized the 
supplies include ARV drugs, laboratory services, prophylaxis. Labour inputs include nurses, 
physicians and other health care workers. 
It is clear from the above discussions that different cost elements make up the HIV/AIDS 
treatment interventions. These costs elements must be identified and valued to determine the 
actual programme costs for the interventions. 
The clients attend treatment at the two clinics on average once every month. These clients 
have been on treatment and thus their treatment history is known. Any additional days 
required for them are communicated to them, so the treatment process is quite uniform and 
the items identified are relevant. However in cases that the items are not relevant to the 
treatment of a client, he or she skips it when filling the questionnaire. 
The other cost items including capital costs, overheard costs, and labour costs of the two 
clinics were estimated. These costs were taken from the grants expenditure manual computed 
by Health for All Health clinic. For the Fevers’ unit, I computed these costs from the cost 
items survey by Rosen and Asante (2010). This information is presented in table (5) below  
The process of collecting the cost for this study and the intervention will fully be described 
under the methodology. An important issue in health care is the effects of externalities, which 
are defined as costs incurred or benefits received by third parties who are not directly 
involved in a transaction (Folland, Stano and Goodman).  HIV/AIDS treatment of a pregnant 
woman on ARV provides a benefit of reducing the infection of foetus in her womb. This child 
  
21 
 
may not be part of transaction but may benefit from the reduction in the mother’s ability to 
infect others. 
2.2 Literature review 
The infection with HIV/AIDS has been associated with increased in mortality rate. 
Colebunders, Ryder, Francis et al (1991), found out that disease progression is higher in 
Africa, compared to developed countries. In Uganda for instance, Morgan, Mahe, Mayanja, 
Okongo, Lubega and Whitworth (2002) found out that the median progression rate of 
HIV/AIDS to death to be 9.8 years. HIV/AIDS disease has thus been a source of increase in 
mortality in Africa. After the introduction of ARV therapy, Bakari, Urasa, Pallangyo, Swai, 
Mhalu, Biberfield and Sandstrom (2004) also  found out that death rate among Tanzanians 
infected with HIV/AIDS is higher than among people from the developed world. However, 
there are similarities between disease progression rate among Tanzanians and people from the 
developed world. The introduction of antiretroviral therapy was to minimize the progression 
of the disease and also prolong the life of those infected with HIV virus. 
 There have been various researches conducted on the ARV treatment and various health 
outcomes. This has established that the application of ARV has been effective in reducing 
morbidity and mortality due to HIV/AIDS. 
In a study, Beck and his colleagues (1999), took up the challenge and conducted a study with 
objective of investigating the association between usage of ARV drugs, hospital usage and 
change in morbidity among HIV/AIDS patients. This study was a prospective cross-sectional 
design, and collected data through the National Prospective Monitoring System (NPMS), a 
system designed to examine use, cost and outcome of HIV/AIDS services provided in 
Hospitals in England. Data was collected on patients’ average hospital usage, average HIV 
related opportunistic infections and the percentage usage of ARV drugs by patient. Results 
showed a reduction in inpatient hospital usage among patients. The average inpatient days 
was reduced. Treatment of related opportunistic infections was also reduced drastically. The 
percentage of ARV drugs usage also increased. 
Evidence emerged that a combination drugs for treatment of HIV/AIDS is more efficacious in 
minimising disease progression (Gulick, Mellors, Havlir et al (1997) and mortality (Palella, 
Delaney, Moorman , et al.  (1998) among PLWHA. This findings developed interests among 
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researchers. Much of the researches tried to find out the cost effectiveness of some of the use 
of combinations ARVs for the treatment of HIV/AIDS. 
Also, research in France found a reduction in hospital cost among PLWHA after being 
enrolled on highly active antiretroviral therapy (HAART). The study was designed to assess 
the impact of HAART on the health status and hospital costs in severe HIV-infected patients 
followed in a hospital in France. The study considered the first 500 patients who received the 
HAART treatment, and had CD4+ cell count below 250/mm³. Markov modelling was used to 
determine the description of patients among varying health states (including) death. The 
financial charges and HAART treatment costs in the hospitals were also computed. Health 
states of patients, determined by both CD4 counts and viral loads, over the 14 month period 
were used to show clinical changes in the patients. A simplified model based on CD4 counts, 
over two 14 month periods were used to assess the economic impact of HAART initiation. 
This was done to assess effect before initiation and also after initiation of the HAART. 
Results from the study showed that from day 0 – 14 months, the proportions of patients in the 
least severe state defined as CD4+ ˃ 100/mm³ and viral load ˂ 500 copies/mL increased from 
1 % to 50%. The proportion with more than 100 CD4+ cells/mm³ increased from 17% to 
80%. On the other hand, hospital charges fell from five thousand one hundred and thirty eight 
French francs ( Fr 5,138) per patient month to three thousand one hundred and thirty six( Fr 
3,136), representing about 39 per cent reduction in hospital costs. There were minimal 
increases in ARV treatment cost but the drastic reduction in hospital cost has compensated for 
the increase ARV treatment (Le Pen, et al, 2001). 
Researches were conducted in England to find out whether the use of highly active 
antiretroviral therapy will be cost effective compared to new approaches to using 
antiretroviral therapy for the management of HIV infection among English HIV infected 
individuals. The researchers designed a study that used a Markov modelling to simulate the 
progression of HIV infection and to estimate the cost, effects and the cost effectiveness of the 
treatment options under investigation. The health states were based on CD4 counts of the 
participants. This provided the basis upon which cost effectiveness of HIV treatment was 
modelled. The cost effectiveness was assessed by dividing the differences in costs by the 
differences in health outcomes, i.e. the life years or quality adjusted life years (QALYs) 
saved, between the treatments under consideration. This was used to determine the 
incremental cost effectiveness ratio (ICER). The interventions were HAART, which was dual 
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NRTI therapy plus a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor 
compared to dual NRTI therapy. The health outcome measures included projected life 
expectancy, cost-effectiveness in GBP per life year saved and QALYs saved. Results showed 
treatment effect of therapy with HAART produced incremental cost effectiveness ratios of 
£14 602 per life-year saved and £17 698 per QALY saved, which suggested that the use of 
HAART in England is at least moderately cost-effective compared with treatment to two 
NRTIs alone (Miners,  Sabin,  Trueman et al 1999). Another simulation study was conducted 
in the US to find out the effect of combinatorial ART treatment for HIV/AIDS. The drugs 
included zidovudine, lamivudine, and indinavir. The study was designed using a computer-
based simulation model of HIV disease to compare alternative ART treatments. The main 
data for the study was obtained from major clinical trials (e.g. AIDS Clinical Trial Group 320 
Study, John Hopkins HIV Clinic Cohort study, the Italy, Netherlands Canada and Australia - 
INCAS trial. Cost data was based on national AIDS Cost and Services Utilization Survey. 
The researchers used indicators including changes in both CD4 cell count and the HIV RNA 
level, the development of opportunistic infections, adverse reactions to medications, and death 
to simulate course of disease in a hypothetical cohort of HIV infected persons. Health 
outcome measures included primary and recurrent opportunistic infections, life expectancy, 
life expectancy adjusted for quality of life, and lifetime direct medical costs, and cost 
effectiveness in dollars per quality – adjusted year of life gained. The efficacy of ART 
treatment was measured by a reduction in the HIV RNA level, resulting in the CD4 cell count 
and reduction in the probability of opportunistic infections and AIDS related death. Results 
from this study showed that, in comparison with no therapy, life expectancy adjusted for 
quality of life for three drug therapy increased from 1.53 to 2.91 years, and per- person life 
time costs increased from USD 45,460 to USD 77, 300. The incremental cost per quality 
adjusted life year of life gained, as compared with no therapy, was USD 23,000. This means 
that treatment of HIV infection with a combination of three antiretroviral drugs is cost-
effective use of resource. This meant that treatment of HIV infection with a combination of 
three antiretroviral drugs is cost-effective use of resources (Freedberg, Losina, Weinstein, et 
al. 2001). 
The above studies gave vivid illustration to the efficacy of antiretroviral therapy. However, 
these studies were conducted in developed countries, and there are grounds to question 
whether this can be directly applied in (sub-Saharan) African countries. For instance it has 
been established that there are greater disparities in health care spending between the 
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developed countries and the developing (African) countries. The health care per capita costs 
in the United States of America (USA), Norway and United Kingdom (UK) are USD 6,350, 
USD 4,307 and USD 2,597 respectively. In a sharp contrast, the health care per capita in 
Nigeria for instance is USD 45. Also, developed countries have higher access to health as 
most of their health care expenditure is publicly financed. Public health care expenditure in 
the UK for instance is 87 per cent. In Norway it is 84 per cent, and in the US it is 45 per cent. 
Out of pocket payments are 12 per cent, 15 per cent and 13 per cent respectively in these 
countries.  In sharp contrast, in developing countries a very high percentage of health care 
expenditure is financed through out of pocket payments. (Olsen, 2009).  These disparities by 
extension come into play in the treatment of HIV/AIDS. Due to these factors, it should be 
argued that a further investigation of the effects of cost-effectiveness of ARV medication be 
done in the developing countries. 
Will the findings in the above studies apply to least developed countries as well? Some few 
studies conducted in some developing countries concerning ARV treatment are worth 
evaluating. 
Efforts to fight the HIV/AIDS pandemic in sub-Saharan Africa have been limited by lack of 
access to the counselling and testing services. Sweat et al (2000) conducted a study in Kenya 
and Tanzania to test the impact, cost and cost-effectiveness analysis for voluntary counselling 
and testing (VCT) of HIV-1. In this study cost effectiveness was a hypothetical cohort of 10 
000 people seeking VCT in some cities in East Africa. The main outcome measures estimated 
for this study were programme cost, number of HIV-1 infections averted, cost per HIV-1 
infection averted and cost per Disability Adjusted Life Years (DALY) saved. Modelling was 
done on the impact of targetting VCT by HIV-1 prevalence of the client population. The 
research also modelled the impact on couples who receive VCT compared to individuals. 
Sensitivity analysis was also done on all model parameters. Results from the study show that, 
during the subsequent years HIV -1 VCT was estimated to avert 1104 HIV -1 infections in 
Kenya and 895 HIV-1 infections in Tanzania. The cost per HIV-1 infection averted was USD 
249 in Kenya and USD 346 in Tanzania. The cost per DALY saved was USD 12.77 and USD 
17.78 representatively. The intervention was also very cost-effective for HIV-1 infected 
people and those who received VCT as a couple. The cost-effectiveness of VCT also 
improved significantly when targeting VCT to population with HIV-1 prevalence and 
couples. 
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The effect of the HIV/AIDS pandemic is not limited to adults only. Even children are 
affected. Children born to mothers who have HIV/AIDS are at risk of getting infected with 
HIV/AIDS. According to the UNAIDS report (1998), about 90 per cent of the children who 
got infected with HIV/AIDS through mother to child transmission were in sub-Saharan 
Africa. Marseille and his colleagues decided to conduct a study into cost effectiveness of 
HIVNET 012 nevirapine regimen in reducing mother to child transmission. The researchers 
assessed the cost-effectiveness in hypothetical cohort of 20 000 pregnant women in sub-
Saharan Africa. The main outcome measures included programme cost, paediatric HIV-1 
cases averted, cost per case averted, and cost per disability adjusted life. The study model 
compared the costs, outcomes, and cost-effectiveness of five short-course antiretroviral-based 
strategies aimed at decreasing mother to child transmission of HIV-1 with no intervention. 
The regimens included HIVNet 012 (targeted), HIVNet 012 (universal), PETRA-A, PETRA-
B, and Thai (targeted). Results show that HIVNet 102 regimen would avert 603 cases of HIV-
1 in babies, cost USD83,333 and generate 15862 DALYs, for universal treatment with 30 per 
cent HIV seropositive prevalence. The associated cost – effectiveness ratios were USD 138 
per case averted or USD 5.25 per DALY. At 15 per cent seropositive prevalence, the 
universal treatment option would cost USD 83,333 and avert 302 cases at USD 276 per case 
averted or USD 10.51 per DALY. HIVNet 012 would cost 141 922 USD and avert 476 cases 
at USD 298 per cases averted or USD11.29 per DALY, for targetted treatment at 30 per cent 
HIV-1 seropositive prevalence. With seropositive prevalence higher than 3.0 per cent for 
universal and 4.5 per cent for targetted treatment, the HIVNet 012 regimen was likely to be as 
cost effective as other public health interventions. The sensitivity analyses show that the cost-
effectiveness analysis was robust under a wide range of parameters. The result shows that in 
high seropositive prevalence settings, HIV 012 regimen can be highly cost-effective. It also 
shows that nevirapine therapy could have a major public health impact at a reasonable cost in 
areas with lower seropositive prevalence when multi dose regimens are not cost effective 
(Marseille, 1999). 
A study was conducted in the Republic of South Africa, to compare cost effectiveness of 
some patients on the highly active antiretroviral treatment for HIV / AIDS and a comparison 
not receiving the ARV.  The study involved all HIV infected people who were assessing 
HAART at the health care facilities affiliated to the University of Cape Town, in South 
Africa. These patients were included in the large scale Cape Town AIDS Cohort study.  These 
were included in the treatment group, while patients who have never accessed ARV treatment 
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were included in a match comparison (control) group. The study ensured that the two groups 
were matched on immunological, clinical, social and economic variables.  Results from this 
study also showed that HAART is a cost-effective intervention in South Africa. HAART 
treatment is also seen as cost saving when treatment cost is reduced further (Badri, Maartens, 
Mandalia et al, 2006). 
In a related study in Burundi, some researchers found that the use of ARV treatment is cost – 
effective. The study was conducted to assess the cost effectiveness of the HIV care provided 
by a non-Governmental Organisation (NGO), called Society of Women Against AIDS 
(SWAA).  The NGO set up a clinic that gave primary care treatment including ARV  to 
PLWHAs. They also gave social and psychological support including, home visits food 
support, counselling among others ( Renaud, Basenya Borman, 2009). 
The items included in the measure of cost effectiveness were different in the various settings. 
For instance in the study in Burundi, the treatment centre was a private NGO, and the items 
included in the treatment was home visit and food. There is not much evidence that these 
costs are replicated elsewhere in ARV services for PLHWAs. Also, evidence showed that 
transportation cost is a big burden for patients in accessing health care, and has been an 
important reason depriving patients from accessing health care (Løchting, 2008). However 
this very important aspect of health care cost has not been considered in both the study done 
in South Africa and Burundi. The estimation of the cost items were also not without 
questions. In the Burundian study, the cost of the various drugs were estimated from three 
different sources (and then averaged, due to unavailability of accurate data.  The Burundian 
study also used Disability Adjusted Life Years to measure cost-effectiveness. However as 
noted above, DALYs are known to be bias towards the poor and the elderly. 
Finally, none of the studies conducted involved traditional medicine as comparator. This 
study however uses a traditional medicine as comparator since traditional medicine has been 
an important part of African health delivery system. 
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2.3 ARV Treatment in Ghana 
Ghana has adopted some pragmatic measures towards HIV/AIDS prevention and treatment. 
Ghana established the National AIDS/STI control Programme in 1987. The provision of ARV 
drugs was integrated into the public health care system from 2003 (NACP, 2005). The main 
types of ARV drugs use in Ghana are combination of nevirapine, zidovuvine, stavudine, 
lamivudine drugs. Also patients use firstline and second line drugs (Rosen and Asante, 2010). 
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CHAPTER 3: METHODOLOGY 
3.0 Introduction  
This chapter describes the research techniques employed in collecting the data for the study. 
The concepts tackled in this chapter include research methods, ethics of research, population 
and sample size and access to the research area. The sites for the study are  the Fevers’ Unit of 
the Korle-Bu Teaching Hospital and Health for All Herbal Centre at Owuram (near 
Asamankese) , in the West Akyem Municipality in Ghana. 
 They both provide counseling and support for the PLWHA, but the Fevers’ Unit at Korle Bu 
provides ARV treatment, whereas the Health for All Herbal Centre provided only herbal 
treatments (thus no ARV treatment for the patients). The treatments in these two centers 
ensure that the study obtained two different groups. Those on Antiretroviral treatment, ARV 
KBTH and  those on herbal treatment HERB HFHC. 
Identification, measurement and valuation of cost are important elements in cost utility 
analysis (Drummond et al, 2005). Prior to conducting the study, I held a meeting with some 
officials in the two centers and requested permission from them to enable me carry out the 
study in their centers. The counselors at both the Fevers’ Unit at Korle Bu and the Health for 
All Herbal Centre explained to me they have been helping other researchers in collecting data 
from their clients.  I was briefed on the routines in accessing ARV treatment at Fevers’ Unit 
and the DnT veramin 1 & 2 Herbal treatment at the Health for All Herbal Centre. The medical 
treatment history of the clients in both centres is known. The study used out-patient clients. 
After diagnoses, these clients are put on the drugs as medically feasible. They come for 
reviews monthly, unless it becomes necessary to request them to schedule another review 
within the month. On average, they are given care ones every month. The meeting I had 
earlier with the two clinics enabled me to be acquainted with the processes involved in the 
treatment and aslo to identify the necessary cost elements. The costs identified at the monthly 
medical visits include laboratory analysis, consultation, purchases of the appropriate drugs 
from the pharmacy (at either of the health centers) etc (refer to the appendix I and II). The 
patients pay for the services rendered at the two clinics. The costs are valued in Ghana Cedis 
(GHC). The cost data is directly taken from the patients using the questionnaire so the 
valuation and the measurement are done concurrently.  
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I wrote a follow up letter and attached my proposal to the two centres, and was given a green 
light. After developing the questionnaires and seeking clearance from my supervisor, I sent 
the questionnaires through the internet to the research assistants for the data collection at the 
two centers. I was also in touch with them by mobile phone and on the internet throughout the 
period of the data collection. When they were not clear with anything concerning the data 
collection, they sought clarification from me before going on to ensure that the study went on 
successfully. 
3.1 Sample 
The study used a cross- sectional study design and a systematic sampling strategy, which 
ensures that every nth element is selected for the study. In my study, nth is equal to every 2
nd
 
client. The inclusion criteria were being an adult (man or woman) between the ages of 20 and 
55 and being on treatment at either the Fevers’ Unit at Korle Bu or Health for All Herbal 
Clinic. People who are HIV/AIDS seronegative, those not attending treatment at the two 
centers even though they may be seropositive, and those who are HIV-positive but either 
below twenty or above 55, and also those who in any other way did not meet the inclusion 
criteria were excluded from the study. At each centre during the clinical days, the staff who 
attended to the HIV/AIDS clients asked second male or female who attended either of the 
clinics and met the inclusion criteria if they would be willing to take part in the study. None 
of the clients turned down the request. However, at Fevers’ Unit, one lady who was HIV 
positive but was 19 years old was not given the chance to take part since she did not meet the 
age criteria. Each participant was referred to the research assistant who guided him or her 
through answering the questionnaire, after asking for his or her informed consent. 
A total of 51 HERB HFHC participants and 55 ARV KBTH participants participated in the 
study. 
3.2 Ethical Considerations 
Ethical considerations are a well-known guideline in conducting social research. Cavan 
(1977) defined ethics as ‘a matter of principled sensibility to the rights of others.’ There are a 
lot of ethical considerations in conducting a research especially in a sensitive area as 
HIV/AIDS, which I set out to do. Some ethical considerations applied in the research as 
enumerated by Santrock (2003), includes: 
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3.2.1 Informed consent 
This states that what the study was about and any (potential) risk the participant may be 
exposed to must be explained to the participant ahead of starting the study. This enables the 
participant to decide whether to partake in the study or not. Additionally, the participant has 
the right to withdraw from the study at any time even if he or she agreed to take part in the 
study. 
3.2.2 Confidentiality 
This gives the responsibility to researchers to ensure that data collected from research   
participants be kept from other third parties. The data should be kept anonymous (if possible), 
in other not to give away the identity of the participants. 
3.2.3 Deception 
This gives the researcher discretion to withhold some sensitive information, which may affect 
the outcome of the study from the participant, until after the study. This also entreats the 
researcher to ensure that diligent care is taken that this does not harm the participants. Finally, 
the participant must be debriefed after the study. 
3.2.4 Debriefing 
This entreats researchers to inform the participants about the purpose of the study, after 
ending the study. This also entreats the researchers to explain to the participants any 
information withheld from them (in the beginning of the study), and the reason these pieces of 
information were withheld from them. 
In my research, I tried as much as possible to follow the ethical guidelines spelt above, even 
though I used research assistants in collecting the data.  I trained the research assistants well 
whilst in Ghana during the summer holidays (in 2011). I was also in touch with them through 
the telephone, during the entire period of data collection. In the first place, some of the 
research assistants I used were the trained counsellors in both centers, who have been working 
with the participants, so the issue of confidentiality has been taken care of. Also, the 
questionnaire did not require participants to disclose their names, so none of them could be 
traced to the questionnaires and get the answers they gave. Again, we sought explicit consent 
from the participants before including them in the study. We explained reasons for conducting 
the study and when some information concerning the effect of the study was withheld from 
them at the beginning of the study, they were debriefed. 
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I believe by following these guidelines, the rights of the participants were respected. 
3.3 Data Collection 
I designed a questionnaire that asks the participants to identify and estimate the cost of the 
various items involve in their treatment, from either the herbal treatment or the ARV 
treatment. They also rate their health effects on the EQ5D5 scales. The Questionnaires can be 
found in the appendix I and II. 
Cost elements were identified based on the information from the two clinics on the routine 
and treatment procedures of the clients. The participants are patrons of either of the two 
clinics. The clinical history of each client on treatment is established, so routine reviews like 
lab test (for CD4 counts improvement), consultation, going to the pharmacy for the drugs for 
the recommended drugs, etc were identified as the main cost items. The patients visit the 
clinic monthly, or as recommended based on their health state.  
In the study, the cost elements considered include the following: 
 Health care resources: These include out of pocket payment for the ARV drugs, the addi- 
tional drugs purchased from the pharmacy, consultation fees and Lab tests/VCT. 
The prophylaxis includes septrine for PLWHA with CD4 count of 350 and above. 
The non-health care resources: these include the transportation cost of patients from and to 
the hospital. Finally, productivity of patients was ascertained. The productivity loss of patient 
is the (value of) money lost due to absence from work when sick or attending clinic.  
An important issue is the time cost. The clients spent their time to come for treatment in the 
two centres. Most of them travel from far away and spend the whole day on receiving 
treatment. Different ways were suggested on including time costs into the study. Luce, 
Manning, Siegel and Lipscomb (1996) stated that time costs could be evaluated by using 
suitable measure of opportunity cost, to convert the time cost as dollar (monetary) cost and 
include this in the numerator. In my study, self employed people are also part of the study. 
Most of these people worked in the informal sector as farmers, market women, artisans, and 
others who work in the formal sector. Incomes are expected to vary. The study requested that 
the clients estimate the income they lose through the time of the treatment in the year. 
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The cost items in the questionnaire were estimated by asking the patients to identify the 
appropriate cost items from the questionnaire that applied to them. I used this as a solution 
because, most of the people who are self employed (in the informal sector) will be highly 
undervalued when minimum wage is used to estimate productivity cost. The costs taken 
directly from the hospital, which includes the capital costs, HIV/AIDS subsidy for ARV can 
be found in table 5. 
3.5 Quality Adjusted Life Years (QALYs) 
   In CUA, the health benefit as stated earlier is described using non-monetary measures. The 
effectiveness measure in this study is QALY. The QALY is determined by the EQ5D5 scale. 
The participants are asked to value effects after the treatment on their health state (as at the 
time they are taking part in the study) by marking their health state on the EQ5 D5 VAS scale. 
They also answered questions concerning their health on five health dimensions, based on a 
five scale (refer to appendix i). 
Data were collected using the EQ5D5, a structured questionnaire with closed ended questions. 
The questionnaires were pretested using 6 clients at Fevers’ Unit and 2 clients at Health for 
All Herbal Centre. These clients were not involved in the study. The questionnaire was 
divided into three sections- A, B and C. Section A captures the demographic characteristics of 
the participants. Section B assesses the Cost items and Section C assesses the effect of the 
treatment. The questionnaire is in English. The research Assistants and the counseling staff of 
both clinics, who assisted in the administration of the questionnaires, could speak the three 
main local languages, Ga, Twi and Ewe, so we decided that should any participant have 
difficulty in reading in English language, the questionnaire will be translated for him or her. 
However most of the participants have good knowledge of the English language so there was 
less difficulty in the data collection.  When a participant had difficulty in understanding any 
concept, the research assistants came in to explain. This ensured that the study went on 
successfully. 
3.4 Statistical analysis 
 
The EQ5D5 Questionnaire was used to measure the QALYs of the participants. The QALY 
participants were calculated based on the health profile in the questionnaire. The crosswalk 
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from Zimbabwe was used to compute the QALY. The costs and the QALYs calculations are 
based on one year (2011). The participants’ medical histories are known since they have been 
patrons in the two clinics. The statistical analysis done on the data include regression analysis 
used to assess the effects of treatment on the QALYs of the partcipants. The chi-square test 
was used to compare the effects of age, civil status employment on accessing health at the two 
clinics. The independent sample t-test was used to assess the QALY and the Mann-Whitney 
U-test was used to assess cost differences in the two treatment centers.The Mann-Whitney U 
test was used because of somewhat skewed cost data. I used SPSS version 19 and Excel  
version 2010 to analyse the data. In order to calcite the average costs the midpoint in each 
cost in the questionnaire is used. The cost categories above GHC80 are pegged at GHC100. 
Information gathered from the field shows that maximum average cost of the cost items will 
be GHC 100, for most clients. In addition, I will present the ICERs from both the societal and 
the individual health care payer perspective, with and without the productivity cost. 
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CHAPTER 4: DATA ANALYSIS 
4.1 Demographics 
 frequency percentage 
GENDER    
                    Male 
                   Female 
AGE 
20-29 
30-39 
40-49 
50-55 
MARITAL STATUS 
Single 
Married 
Divorced, 
Separated,Widowed 
EDUCATION 
None 
Primary 
Secondary 
Tertiary 
EMPLOYMENT 
Employed 
Self employed 
Unemployed 
 
53 
53 
 
21 
35 
32 
18 
 
27 
55 
23 
 
3 
29 
64 
10 
 
31 
60 
14 
 
50 
50 
 
20 
33. 
30 
17 
 
25 
52 
22 
 
3 
27 
60 
9 
 
29 
57 
13 
Table 1: Demographic characteristics of the participants 
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For demographic characteristics of the sample, see table 1, above. The sample consists of 53 
males and 53 females each, and majority of the patients have finished secondary education 
and are self employed. 
4.2 Analyzing the differences between the two centers with respect to 
demographic variables 
The Chi-square analysis of the data is presented below. The hypothesis based for example on 
gender is then 
H0: There is no difference in the proportion accessing the two health facilities based on 
gender. 
H1: There is a difference in the proportion accessing the two health facilities based on gender. 
As can be seen from the results from the table 2, below, the variables gender and marital 
status, show a small and non-significant difference between the health centres.  Although 
there are some indications that patients on ARV (from the Teaching Hospital) are older, less 
self-employed and have higher education than patients at the herbal clinic, there are no 
significant differences for these variables either. This could be due to small sample size 
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Variable 
                                               GROUPS 
HFAHC (herbal)  KBTH (ARV) p-value for 
difference 
 Observed n percentage Observed n percentage  
Gender: 
   Male 
   Female 
AGE 
  20-29 
  30-39 
  40-49 
  50-55 
MARITALSTATUS 
  Single 
Married 
Divorced, separated, 
  
EMPLOYMENT 
Employed 
Self Employed 
Unemployed 
 
25 
26 
 
14 
17 
14 
6 
 
14 
24 
13 
 
 
11 
31 
9 
 
49 
51 
 
27 
33 
27 
13 
 
27 
47 
26 
 
 
22 
61 
18 
 
28 
27 
 
7 
18 
18 
12 
 
13 
31 
11 
 
 
20 
28 
6 
 
51 
49 
 
12 
33 
33 
22 
 
24 
56 
20 
 
 
37 
52 
11 
0.85 
 
 
0.194 
 
 
 
 
0.539 
 
 
 
 
0.282 
 
Table 2: Demogaphic of the participants by groups 
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4.3 Analysing the differences between the two centers with respect 
to costs and QALY 
4.3.1 cost 
An independent t-test was conducted to compare the health care payers’ costs of KBTH 
Fevers’ Unit and the Herbal Clinic. The cost differences are skewed, therefore we use the 
bootstrapping percentile method of 10 000 samples. There is significant difference between 
the health cost of KBTH (mean=338, SD=158) and the herbal clinic (mean=195, SD=101). 
The p-value 0.00 is less than the 0.05 significant level, hence there is a difference in costs. 
The patients at the Fevers’ Unit (at the Teaching Hospital) have the higher cost. This may be 
because of higher cost of medication at the teaching hospital. 
4.3.2 QALY 
The independent t-test for the two groups shows that there is a significant difference between 
the quality adjusted life years gained by the two groups. The average score for KBTH is 0.84, 
(SD=0.08) and Herbal Clinic 0.69, (SD=0.10) showing that a higher QALY for patients from 
the Fevers’ Unit (Teaching hospital). This means that the QALY level attained by using ARV 
drugs from the Fevers’ Unit is higher than the QALY level attained from the herbal treatment. 
Variable Mean difference 
HFAHC-KBTH 
95% confidence Interval p-value 
lower upper 
Cost -142.15 -195 -94   0.01* 
QALY -0.15 -0.19 -0.12 0.01+ 
Table 3: Test results with the p-values of the costs and QALY 
Footnote: 1.*Bootstrap confidence interval and Mann-Whitney U-test 
                 2. + Independent sample t-test 
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4.3.3 Regression 
Multiple regressions showing the combined effects of the drugs on QALY is shown in the 
table. 
Variables B P-Value Lower 
bound 
Upper 
bound 
Dependent  
(QALY) 
 
 
   
 
(Constant) 
ARV 
Other drugs 
Prophylaxis 
 
0.71 
0.12 
-0.04 
0.06 
 
0.01 
0.01 
0.01 
0.01 
 
 
0.68 
0.08 
-0.08 
0.02 
 
 
0.74 
0.16 
-0.09 
0.10 
Table 4: Regression results for the effects of drugs on QALY 
  
Looking at the combined effect of the drugs (prophylaxis, ARV and other drugs), all the three 
drugs have a p-values less than 0.05, showing a significant effect on QALY. 
The estimated regression model is: QALY=0.71+0.12 *ARV+0.06*prophylaxis-0.04* other 
drugs 
The R square value is 0.44. This shows that 44 per cent of the variation in QALY in the two 
groups is explained by the prophylaxis, ARV and the other drugs. 
ARV, which is only given to patients at the teaching hospital, has the greatest effect on 
QALYs. Prophylaxis and other drugs, which are given to patients in both health centres have 
smaller effects. 
However, from the regression results, other drugs do not add to the QALY of the patients. 
This is probably mainly due to herbal treatment (DnT Veramin 1 & 2) being included in the 
‘‘other drugs’’ category, and these patients have a lower level of QALY than patients at the 
Teaching Hospital. However, it may be explained with the fact that other drugs are given to 
treat opportunistic infections only, resulting in the negative relationship between this and the 
ARV, prophylaxis and QALY. 
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4.4 COST EFFECTIVENESS 
To calculate the incremental cost effectiveness ratio, we need to identify all the components 
of the two treatment strategies.  In order to assess the additional cost per QALY gained in 
treating HIV/AIDS, we need to calculate the incremental cost effectiveness ratio (ICER).  The 
cost components from the hospitals are expected to differ much more between the health 
centres than the health care payers’ costs. The data taken from the costs and proposal data of 
Health for All Herbal Clinic and some secondary sources for Fevers’ Unit of the Korle Bu 
Teaching Hospital are presented in table 5, below. 
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Identification of cost 
 
KBTH 
(ARV) 
n=55 
HFAFC (DnT VERAMIN) 
  n=51 
Labour cost (staff)  *    
Physical structure* 
Admin support: 
NACP&GHS 
DnT veramin 
Support from 4H (NGO)* 
ARV drug (subsidy)* 
 
Total cost from clinic 
 
Patient cost: 
ARV 
Other drugs 
Prophylaxis 
Consultation 
Lab 
Outpatient 
Patient cost without 
productivity (total) 
Patient time (productivity 
cost) 
Patient cost with 
productivity (total) 
Total cost per client 
(from societal persp) ¹+³ 
 
Total client cost ³ - ² 
(without prod cost) 
 
Mean QALY 
                    
 
53 
27 
 
164 
 
 
202 
 
446¹ 
 
53 
29 
29 
10 
14 
31 
 
166 
 
144² 
 
 
310³ 
 
756 
 
612 
 
 
0.84                      
3 
3 
 
0.00 
20 
25 
0.00 
 
51¹ 
 
0 
23 
12 
10 
16 
21 
 
82 
 
99² 
 
 
181³ 
 
232 
 
133 
 
 
0.69 
Table 5: Mean annual HIV related cost per patient from the societal 
perspective                    
Footnote: All costs are in Ghana cedis (GHC). *The cost items are   taken from Rosen & 
Asante 2010 (for ARV treatment) and from cost data from Herbal clinic. 
¹ total costs from each of  the two clinics. 
² productivity costs. 
³ total patients cost with productivity cost.     
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An issue in cost utility analysis is how to deal with productivity cost. Some experts suggest 
they should be eliminated totally. Others said that they should be included in either the 
denominator or the numerator. There is no conclusive agreement between the various views. 
However, a suggestion is that we do the analysis with the productivity cost and then also 
present the analysis without the productivity cost (Drummond et al, 2005). 
This study adopted the latest view. The ICER with the productivity cost and the ICER without 
the productivity cost are presented below. The societal perspective as stated earlier considers 
all costs including subsidies, the individual patients’ cost and other related costs. 
 
Societal perspective 
The ICER is 
                     
                   
 
The ICER (from the societal perspective) with the productivity cost is presented below. 
 ICER = 
       
         
 = 
   
    
 = 3,493 
From societal perspective with productivity cost, the ICER  is GHC 3,493/QALY. 
 From the societal perspective, the average cost for treating HIV using ARV is GHC 756. The 
average cost of treating HIV using the herbal drug, DnT veramin, is GHC232. The 
productivity costs are 144 and 99 the ARV and HERBAL respectively.  The productivity 
costs are deducted and the ICER is presented. The average QALY of patients on ARV is 0.84. 
The average QALY of patient on herbal treatment is 0.69. 
The Incremental cost effectiveness ratio: 
                                                       = 
       
         
 = 
   
    
 =3,193 
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From the societal perspective (without productivity cost), the The ICER  is GHC3,193 per 
QALY. 
The individual patient’s perspective 
The individual payer perspective, takes into account only the costs incurred by the individuals 
in treating HIV/AIDS. The cost elements are taken from the questionnaire. Therefore other 
costs (for instance, capital costs) are not included. 
From the individual patient perspective with the productivity cost, the ICER is 
            
        
    
  =  
   
    
  = 860 
Health care perspective ICER =   GHC 860/QALY 
From the individual health care payer persective with productivity cost the cost per QALY for 
a using ARV is GHC 860/QALY. 
 
ICER from individual perspective without the productivity cost is calculated by deducting the 
productivity costs from the patient’s cost before calculating the ICER. The total patient costs 
from Fevers’ Unit and the Health for All Herbal Clinic are GHC310 and GHC181, with 
GHC144 and GHC99 as respectively as productivity costs. From the Fevers’ Unit, GHC 310 
minus GHC144  is GHC166. From the Herbal clinic, GHC181 minus GHC99 is GHC82. 
The ICER without productivity costs is: 
          
      
         
  = 
  
    
 = 560 
From the individual health care payer (patient’s) perspective without the productivity cost, the 
ICER is GHC560 per QALY. 
Drummond et al. (2005) stated that in order to make decisions and draw valid conclusions, the 
ICER is compared with other measures for instance from published thresholds. Babimguda et 
al (2009), for example, used a threshold of per capita GDP of 1-3 suggested by WHO, in their 
CUA study in Uganda. I will also use this threshold.  
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According to the CIA world fact book, Ghana’s GDP per capita is USD3,100 (www.cia.gov). 
In December 2011, USD 1 equals GHC1.62 (oanda.com). When we use the December 
2011exchange rate for the US Dollar, then USD3,100  translates to GHC5,022. All the ICER 
values calculated from both societal and individual payer perspectives (which included or 
excluded productivity cost) are lower than the threshold value. The ICER from societal 
perspective which included the productivity cost and the ICER without the productivity cost 
are GHC 3,493/QALY and GHC 3,193/QALY respectively. These are lower than the 
threshold of GDP per capita, i.e. GHC5,022. Also, the ICER from the individual payer 
perspective with the productivity cost and the ICER without the productivity cost are 
GHC860/QALY and GHC 560/QALY respectively. These are also lower than the threshold 
value of the per capita income of GHC 5,022.   This means that ARV treatment is cost 
effective compared to treatment given at the herbal clinic. The results are summarized in 
figure 2. 
Sensitivity analysis 
I conducted sensitivity analysis based on varying the cost data for the patients on ARV. Their 
choice is arbitarilily done only on the view that these costs are higher . The sensitivity 
analysis is done to check, the effect of changes in their cost. The costs are changed by  ten 
percent lower or higher ,  twenty percent lower or higher, and thirty percent lower or higher  
respectively. The results are presented in table 6 below. 
 ARV Herbal ICER (GHC/QALY) 
Total from table 5 
10% down 
10% up 
20% down 
20% up 
30% down 
30% up 
756 
680 
832 
605 
907 
529 
983 
232 
232 
232 
232 
232 
232 
232 
3,439 
2,987 
4,000 
2,487 
4,500 
1,980 
5,007 
 
Table 6: sensitivity analysis of cost of HIV/AIDS treatment in Ghana 
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The range between the cost of HIV treatment in the two clinics is wide. By varying the cost, I 
tried to estimate how changes in the various costs up and down will affect the ICER. In effect 
as could be seen from the table 6 above, the effect of changes between ten percent  and thirty 
percent higher or lower of the ARV treatment cost  will still be cost effective.  This is because 
the ICERs for the sensitivity analysis are still less than society’s WTP, i.e. GHC5022.  The 
cost utility analysis is thus robust. 
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Figure 2: Comparison of the ICER and WTP (which is per capita GDP of Ghana) 
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5.0 Discussions and conclusions 
 
Ghana has been among the countries in sub-Saharan Africa that have scaled up the treatment 
of HIV/AIDS using antiretroviral treatment. The usage of some herbal drugs for the 
management of the disease has moderate patronage among some people. This study intends to 
find out cost and the utility of the HIV/AIDS treatment in Ghana. The study compares the 
herbal treatment to ARV treatment. 
Even though the groups differ on wealth and age, the demographic characteristics of 
participants in the group that uses ARV and the group that use the Veramin DnT 1&2 herbal 
drugs are quite similar. This allows for meaningful and valid comparisons. 
 
A point to note here is that, there are higher percentages of older people in the group 
accessing ARV as compared to people accessing herbal drugs. These elderly people may have 
higher income than the younger people in the herbal clinic. 
Also, the settings of the two clinics are different. The herbal clinic is located in the rural 
district in the country side. The facilities and staff cannot match that of the Fevers’ Unit. The 
Fevers’ Unit is located in the main city of Accra. It is housed in the same premises and shares 
some of the resources of the University of Ghana Medical School, and the Korle Bu Teaching 
Hospital. Staff strength is stronger and recruitment of skilled staff is better as compared to the 
herbal clinic. The provision of better counseling services and medical attention is better at the 
Fevers’ Unit than the herbal clinic. This could also account for the better health outcome for 
the participants on ARV. The clients that the two centres attract may vary economically. 
Since the Fevers Unit is in the city, it may attract people with better socioeconomic status (in 
terms of education, wealth, social amenities) than those who attend the herbal clinic. These 
disparities may also account for the differences in the cost and health outcomes of the two 
groups. 
The independent sample t-test shows that there are differences in the QALYs of the PLWHAs 
receiving ARV treatment as compared to those receiving the herbal treatment. Specifically,  
the mean QALY is higher in the ARV group than in the herbal treatment group. 
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Also, the regressions analysis shows that that the ARV drugs and prophylaxis adds to QALY, 
whiles the other drugs did not add to the QALYs. This means that we can increase the 
QALYs of the patients by putting them on ARV and prophylaxis as appropriate. The other 
drugs including DnTveramin 1 & 2 herbal drugs do not add to QALY.This is because veramin 
may not have antiretroviral effects and also because other drugs are given to the patient 
mostly to treat opportunistic infections.   
A very important analysis in conducting cost utility analysis is the ICER. The ICER result 
from the societal perspective shows that cost per QALY gained is GHC 3,493 (with 
productivity cost) and GHC3,193 per QALY (when productivity cost is excluded). Also, the 
ICER was GHC 860 per QALY when productivity cost is included, and GHC 560 per QALY 
when productivity cost is excluded, when considered from the individual care perspective.  
  In comparison to the GDP per capita, the ICER from the societal perspective is lower than 
the GDP per capita. Also, from the individual payer perspective, the ICER is lower than the 
GDP per capita. From both perspectives the ICER is lower than the threshold of GHC 5,022, 
showing that the treatment of HIV/AIDS using ARV drugs is cost effective. 
 Sensitivity analysis is conducted by varying the cost of the ARV treatment up and down 
between ten to thirty percent. The ICERs conducted after varying the costs are compared and 
with the WTP. The results presented in table 6, shows that these ICERs are also less than 
society’s WTP in Ghana. The results are very robust. 
The finding from the study is consistent with other findings reviewed in the literature review 
that shows cost effectiveness of treatment of HIV/AIDS using ARVs.  For instance it is 
consistent with studies conducted by Badri Maartens, Mandalia et al (2006) in South Africa 
and Renaud, Basenya and Borman (2009) in Burundi. However, this is the first study to 
compare ARV to traditional herbal medication. 
The study has policy implication. Based on the analysis, society should fund ARV drug for 
treatments of HIV/AIDS in Ghana, since ARV treatments appeared cost effective from both 
societal and health care perspective. 
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5.1 Limitation of the study and recommendations 
Every human endeavor has limitations and this study is not exempted. In my study, even 
though I tried my best, some of these phenomena, I think are considered limitations in my 
study. I included only point estimates for the societal perspective ICERs. This is because I did 
not have enough information about estimates on uncertainty in cost in other areas than 
included in the questionnaire. If I were to get enough information, I could have done 
modeling in TreeAge (e.g. a cohort simulation).  
I set cost categories above GH80 in the questionnaire to be GH100, based on the experience 
on the field that an average of 100 on most of the cost items in the questionnaire could take 
care of annual expenses. I used cost categories to facilitate rememberance from participants. 
However this implementation may have some biases. 
Fisrtly, the study is constrained by time. The whole research is conducted within a semester. 
Going through the rudiments of research within this short period will not allow for me to 
consider some other aspects of the research. Collecting data and writing this report within the 
short period did not allow me to gather enough information, especially secondary data. 
Financial resource constraint is also a limitation to my study. Research work needs a lot of 
money. One needs to travel to and from the research site, pay research assistants among 
others. Lack of money prevented me from going to the field physically. However, the 
research assistants I used and the counsellors did a good job.  
Again, there is no clear cut consensus among experts in the field concerning the types of cost 
that could be excluded and the one that should be included in the economic evaluations. This 
affects the study too. I used my discretions only on costs included and those who were not 
included.  
There may be recall biases as participants were asked to recall in eliciting responses from the 
participants. They only call those they could remember and may also make intelligent 
guesses. 
I will recommend that financial support be provided to especially the international students 
for data collection, especially to research sites outside Norway. Also, the programme can be 
restructured so that all taught course are taken in the first year. This will enable the students 
focus only on the thesis. 
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5.2 Conclusion 
This research did a cost utility analysis of the treatment of HIV/AIDS in Ghana. Participants 
in the research were taken from a population of PLWHAs accessing ARV treatment at Korle 
Bu Teaching Hospital and DnT Veramin 1&2 treatment at Health for All Herbal Clinic at 
Owuram. The two treatment strategies compared were ARV and Veramin DnT 1&2 herbal 
drug. The results show that ARV drug treatment is cost effective from societal perspective. 
The incremental cost effectiveness ratios were GHC3,493, GHC3,193, GHC 860, GHC560. 
Ghana’s GDP per capita which is used as the threshold is GHC 5,022. The ICER from 
societal perspective and the individual health payer perspective are lower than the GDP per 
capita threshold,  hence the conclusion that ARV treatment is cost effective in Ghana. This 
represents the short term only. The result shows that even though HIV/AIDS has not known 
cure fore now, some gains can be made using ARV. Therefore in maximizing the societal 
welfare, ARV use among the PLWHA will be cost effect (in the short term) in Ghana.  
Individuals with HIV/AIDS should be supported to enroll on the ARV treatment programme.  
This result is for short term only. Further research needs to be done to confirm the long term 
effects. The result has implications for policy making. Based on the results, investing in the 
use of ARV drugs for treatment of HIV/AIDS is a in the right direction. More clinics need to 
be equipped, by recruitment, training and retention of staff, to administer the ARV drugs. The 
subsidy on ARV drugs should be increased and also education on access and the importance 
of enrolment on the ARV treatment programmes needed be intensified. 
It must be noted that Ghana government like every other economic entity is constrained by 
scarce resources. The ARV treatment may not be the only economic activity that may be cost 
effective when implemented, other economic activities, like road, education among others 
also may be cost effective. Looking at the budget constraints not all projects that are cost 
effective could be implemented.  
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Appendix A 
HFHC                                                  Questionnaire 
I am an MPhil student in University of Oslo. I am conducting a research as part of my studies, 
on the cost of HIV/AIDS treatment in Ghana. The questions below are designed to seek the 
costs  on your treatment. Kindly answer the following questions as best as you can.  
 
Part I :DEMOGRAPHY 
Gender                                            Male         [ ]     
                                                         Female      [ ]   
 
Age   (in years)                                     20-29    [ ]    
                                                             30-39     [ ]   
                                                             40-49     [ ]   
                                                             50-55      [ ]   
 
Marital status                                      single    [ ]   
                                                            Married   [ ]   
                          divorced/seperated/widowed   [ ]   
Highest education                                  none  [ ]  
                                                           primary   [ ]   
                                                         secondary  [ ]   
                                                              tertiary  [ ]   
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Employment                                    employed  [ ]   
                                                         self employed  [ ]   
                                                          unemployed  [ ]   
 
 
Part II health care and other costs 
Kindly mark the space showing the costs items and the costs that you spent intreatment 
annually. Each cost item is in New Ghana Cedis 
a. Health care cost 
Anteretroviral         20 or less [ ]    21-40[ ]     41-60[ ]     61-80 [ ]     81 or more [ ] 
Drugs (DNT 1&2 Veramin ) 
   Other drugs           20 or less [ ]    21-40[ ]    41-60 [ ]     61-80 [ ]   81 or more [ ]    
              Prophylaxis           20 or less [ ]    21-40[ ]     41-60[ ]      61-80 [ ]    81 or more [ ]    
            Consultation            20 or less [ ]    21-40 [ ]    41-60 [ ]     61-80 [ ]   81 or more [ ]    
Lab tests/VCT        20 or less [ ]    21-40 [ ]     41-60 [ ]     61- 80 [ ]  81 or more [ ]    
 
Out patient visits    20 or less [ ]    21-40 [ ]     41-60 [ ]     61-80 [ ]     81 or more [ ]    
            Other sectors 
Transport to hospital   20 or less [ ]    21-40 [ ]     41-60 [ ]  61-80 [ ]  81 or more [ ]    
Productivity cost 
            Patient time              100 or less [ ]       200 [ ]       300 [ ]      400 or more  [ ]     
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Care giver time        100 or less [ ]      200  [ ]      300 [ ]     400 or more [ ]     
 
Kindly identify and give the cost of any other money spent that was not mentioned above 
Item …………… cost……….. 
Item …………… cost……….. 
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Appendix B 
KBTH                                                       Questionnaire 
I am an MPhil student in University of Oslo. I am conducting a research as part of my studies, 
on the cost of HIV/AIDS treatment in Ghana. The questions below are designed to seek the 
costs  on your treatment. Kindly answer the following questions as best as you can.  
 
Part I :DEMOGRAPHY 
Gender                                            Male         [ ]     
                                                         Female      [ ]   
 
Age   (in years)                                     20-29    [ ]    
                                                             30-39     [ ]   
                                                             40-49     [ ]   
                                                             50-55      [ ]   
 
Marital status                                      single    [ ]   
                                                            Married   [ ]   
                          divorced/seperated/widowed   [ ]   
 
Highest education                                  none  [ ]  
                                                           primary   [ ]   
                                                         secondary  [ ]   
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                                                              tertiary  [ ]   
 
Employment                                    employed  [ ]   
                                                   self employed  [ ]   
                                                     unemployed  [ ]   
 
 
 
 
Part II health care and other costs 
Kindly mark the space showing the costs items and the costs that you spent intreatment 
annually. Each cost item is in New Ghana Cedis 
a. Health care cost 
Anteretroviral         20 or less [ ]    21-40[ ]     41-60[ ]     61-80 [ ]     81 or more[ ] 
Drugs (ARV drugs) 
   Other drugs           20 or less [ ]    21-40[ ]     41-60 [ ]     61-80 [ ]    81 or more [ ]    
              Prophylaxis           10 or less [ ]    11-20[ ]     21-30[ ]      61-80 [ ]     81 or more [ ]    
            Consultation          10 or less [ ]    11-20 [ ]     21-30 [ ]     61-80 [ ]     81 or more [ ]    
Lab tests/VCT        10 or less [ ]    11-20 [ ]     21-30 [ ]     61-80 [ ]     81 or more [ ]    
 
Out patient visits    20 or less [ ]    21-40 [ ]     41-60 [ ]     61-80 [ ]     81 or more [ ]    
            Other sectors 
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Transport to hospital       20 or less [ ]    21-40 [ ]     41-60 [ ]  61-80 [ ] 81 or more [ ]    
Productivity cost 
            Patient time              100 or less [ ]       200 [ ]       300 [ ]      400 or more  [ ]     
Care giver time        100 or less [ ]      200  [ ]      0300 [ ]     400 or more [ ]     
 
Kindly identify and give the cost of any other money spent that was not mentioned above 
Item …………… cost……….. 
Item …………… cost…………….. 
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